Global Artificial Pancreas Medical Device Landscape Report 2021: Pipeline Products, Products Under Development, Company and Product Overview, Recent Developments – ResearchAndMarkets.com

0
25

DUBLIN – (COMMERCIAL THREAD)–The “Artificial pancreas – Product landscape of the medical device pipeline, 2021” report was added to ResearchAndMarkets.com offer.

“Artificial Pancreas Medical Devices Pipeline Product Landscape, 2021” provides comprehensive product information on the Artificial Pancreas pipeline with a comparative analysis of products at different stages of development and information on ongoing clinical trials.

The artificial pancreas helps people with diabetes, mainly type 1, automatically and continuously control their blood sugar by providing the endocrine replacement function of a healthy pancreas.

Scope

  • Extensive coverage of the developing artificial pancreas

  • The report reviews the details of the main products in the pipeline, including product description, licensing and collaboration details, and other development activities.

  • The report reviews the main players involved in the development of the artificial pancreas and lists all their pipeline projects

  • Coverage of pipeline products according to various stages of development from early development stage to approved / issued stage

  • Report provides key clinical trial data on ongoing trials specific to pipeline products

  • Recent developments in the segment / industry

Reasons to buy

  • Formulate important information, analysis and insight into competitors to improve R&D strategies

  • Identify emerging players with a potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the important and diverse types of artificial pancreas under development

  • Develop market entry and market expansion strategies

  • Effectively plan mergers and acquisitions by identifying key players with the most promising pipeline

  • In-depth analysis of the current stage of product development, territory and estimated launch date

Main topics covered:

1 Table of contents

1.1 List of tables

1.2 List of figures

2 Presentation

2.1 Overview of the artificial pancreas

3 products in development

3.1 Artificial Pancreas Pipeline Products by Development Stage

3.2 Artificial Pancreas – Pipeline Products by Territory

3.3 Artificial pancreas – Regulatory pipeline products

3.4 Artificial Pancreas – Pipeline Products by Estimated Approval Date

3.5 Artificial pancreas – Ongoing clinical trials

4 Artificial pancreas – Pipeline products under development by companies

4.1 Artificial Pancreas Companies – Pipeline Products by Development Stage

4.2 Artificial Pancreas – Pipeline Products by Stage of Development

5 Artificial Pancreas Companies and Product Overview

5.1 Admetsys Corp

5.2 Advanced Biosensors-Ohio LLC

5.3 Beta Bionics Inc

5.4 Beta-O2 Technologies Ltd

5.5 Bigfoot Biomedical Inc

5.6 BioTex Inc

5.7 Cerco Médical SARL

5.8 Converge Biotech, Inc.

5.9 Covalor Medical, LLC

5.10 De Montfort University

5.11 Debiotech SA

5.12 SAS challenged

5.13 Diabeloop SA

5.14 EOFlow Co Ltd

5.15 Giner Inc

5.16 Harvard John A Paulson School of Engineering and Applied Sciences

5.17 Healios Inc

5.18 Humacyte Inc

5.19 Ideal Medical Technologies Inc

5.20 Imperial College London

5.21 Inreda Diabetic BV

5.22 Insulet Corp

5.23 Joslin Diabetes Center

5.24 Kencak SARL

5.25 McGill University

5.26 Medtronic Diabetes

5.27 Medtronic Inc

5.28 Miromatrix Medical Inc

5.29 Pacific Diabetes Technologies, Inc.

5.30 Pancreatum, LLC

5.31 PharmaCyte Biotech Inc

5.32 Polytechnic University of Valencia

5.33 Rensselaer Polytechnic Institute

5.34 Senseonics Holdings Inc

5.35 Stanford University

5.36 TecMed Inc

5.37 The Alfred Mann Foundation

5.38 TypeZero Technologies LLC

5.39 U-needle BV

5.40 Universidad Autonoma de Madrid

5.41 University of California, San Francisco

5.42 University of California Santa Barbara

5.43 University of Cambridge

5.44 University of Florida

5.45 University of Minnesota

5.46 University of Newcastle

5.47 WaveForm Technologies Inc

5.48 XERIS Pharmaceuticals Inc

5.49 Yale University

6 Artificial pancreas – Recent developments

6.1 06 May 2021: Insulet Reports 27% YoY Q1 2021 Revenue Increase

6.2 05 May 2021: University of Cambridge appoints Dr Diarmuid O’Brien as new Managing Director of Cambridge Enterprise

6.3 April 05, 2021: Insulet to Report First Quarter 2021 Financial Results on May 6, 2021

6.4 March 02, 2021: Xeris Pharmaceuticals to Report Fourth Quarter and Fiscal 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021

6.5 February 16, 2021: Medtronic to Announce Third Quarter Fiscal 2021 Financial Results

6.6 November 09, 2020: Xeris Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020

6.7 August 06, 2020: Insulet to Report Second Quarter 2020 Financial Results on August 6, 2020

7 Annex

For more information on this report, visit https://www.researchandmarkets.com/r/294ugj


Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here